Iroquois Capital Group

RS Metrics specializes in providing asset-level environmental, climate, and physical risk metrics tailored for various stakeholders. In 2023, the company partnered with Google Cloud to enhance accessibility to its extensive suite of over 100 metrics through software as a service (SaaS), data as a service (DaaS), and dashboards. Their flagship products, ESGSignals® and AssetTracker, leverage a decade of model-driven architecture and advanced technologies in artificial intelligence and data science to deliver timely, independent, and verifiable environmental insights. The collaboration with Google Cloud enables the creation of efficient climate risk analytics frameworks for lending and investment portfolios, utilizing granular geospatial datasets. ESGSignals® features a comprehensive array of analysis-ready data (ARD) metrics, which are real-time, auditable, and scalable, facilitating objective valuation and informed decision-making in sustainable finance and enterprise risk management.

Iroquois Security Monitoring provides security alarm products and services. ISM specializes in managing residential security alarm systems and provides services such as fire alarm, theft alarm, and smoke alarm installations.

Community Care Solutions partners with rural hospitals to implement pain management programs. Community Care Solutions brings pain management and interventional pain management services to community hospitals.

ACS Partners provides construction services in the commercial and residential markets. ACS' services include renovations to multi-family complexes, student housing complexes, and single-family residential complexes.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an orally active, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer, one in combination with T-DM1 and the other with capecitabine and/or trastuzumab. In addition to tucatinib, Cascadian is advancing two preclinical candidates: CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborations for research and development, including a licensing agreement with Array BioPharma for tucatinib, a research partnership with Sentinel Oncology to discover novel Chk1 inhibitors, and a collaboration with Adimab for novel antibody development. Formerly known as Oncothyreon Inc., Cascadian Therapeutics was founded in 1985 and has undergone significant evolution in its focus and offerings.

Raptor Pharmaceuticals is a biotechnology company based in Novato, California, focused on the development of therapies for debilitating and life-threatening diseases. The company is engaged in the discovery, research, and preclinical development of drug candidates targeting brain disorders, neurodegenerative diseases, genetic disorders, and cancer. Raptor's clinical-stage products include DR Cysteamine, which is undergoing Phase IIb trials for nephropathic cystinosis and Phase IIa trials for non-alcoholic steatohepatitis, as well as Convivia for ALDH2 deficiency and other candidates for Huntington's disease and various forms of pain. Additionally, Raptor is developing preclinical products such as HepTide for hepatocellular carcinoma and hepatitis C, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases. The company collaborates with the University of California, San Diego, on clinical studies involving its drug candidates. Founded in 2005, Raptor Pharmaceuticals aims to address significant unmet medical needs through its innovative therapeutic approaches.

Soligenix, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases and public health solutions. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma that has completed Phase 3 clinical trials, and SGX942, aimed at treating oral mucositis in head and neck cancer, currently in Phase 3 trials. Additionally, it is developing an oral formulation of beclomethasone dipropionate for severe gastrointestinal disorders in early clinical trials. The Public Health Solutions segment focuses on biodefense, including the development of RiVax, a vaccine candidate against ricin toxin, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections that is in pre-clinical development. The company also works on technologies like ThermoVax, aimed at stabilizing vaccines. Soligenix was founded in 1987 and is based in Princeton, New Jersey.

TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.

Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.

Biomoda, Inc., a development state company, operates as an invitro diagnostics company that develops assays or tests to detect cancer. The company's non-invasive diagnostic is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. It also involves in developing collection protocol and diagnostics for other cancers, including breast, oral, prostate, bladder, colorectal, and cervical. The company has an agreement with the New Mexico Institute of Mining and Technology through the New Mexico Department of Veterans Services for a clinical study for the early detection of lung cancer of the state's veterans. In addition, it has a collaborative agreement with Medical Acoustics, LLC to purchase its Lung Flute as part of the collection protocol in a clinical study. Further, the company has contracts with Quintiles Consulting and Alquest, Inc. who help to guide Biomoda through the FDA approval process. It has a strategic relationship with Obio. The company was founded in 1990 and is headquartered in Albuquerque, New Mexico.

VeriTeQ is a technology company based in Delray Beach, Florida, that specializes in identification solutions for animals and emergency situations. Founded in 1993, the company offers a range of products for pet and livestock identification, including a patented, FDA-approved implantable microchip and RFID ear tags for tracking. Additionally, VeriTeQ provides GPS search and rescue beacons designed for use in various applications, such as on aircraft, ships, and by outdoor enthusiasts. The company is also developing a data analytics platform aimed at enhancing evidence-based healthcare by collecting treatment regimen data related to implantable medical devices used in radiation therapy.

CEL-SCI Corporation is a biotechnology company based in Vienna, Virginia, that focuses on the research and development of immunotherapy products for cancer and infectious diseases. Its leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for treating head and neck cancer. Additionally, CEL-SCI has developed a proprietary platform known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the human immune response against various health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and cancer. The company is also exploring other product candidates, such as LEAPS-H1N1-DC for influenza, CEL-2000 and CEL-4000 for rheumatoid arthritis, and LEAPS COV-19 for COVID-19. CEL-SCI collaborates with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy efforts. Founded in 1983, CEL-SCI continues to innovate in the biopharmaceutical sector.

Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery, development, and commercialization of innovative immunotherapies and vaccines for cancer and infectious diseases. Based in Lexington, Massachusetts, the company aims to activate the immune system to recognize and combat cancer cells through a diverse portfolio that includes checkpoint antibodies, tumor microenvironment modifiers, and vaccine adjuvants. Agenus utilizes its proprietary Retrocyte Display platform for antibody discovery and develops a range of therapeutic candidates, including monoclonal antibodies and vaccines targeting various tumor-specific neo-epitopes. The company has several products in clinical trials, including CTLA-4 and PD-1 antagonists, and collaborates with notable partners such as Incyte Corporation and Merck Sharpe & Dohme to advance its immuno-oncology therapies. Founded in 1994, Agenus continues to build its capabilities in research, development, and manufacturing within the field of immunotherapy.

ACE*COMM Corporation provided operations support systems (OSS) and mobile applications for telecommunications service providers and enterprises. Its OSS solutions were applicable to various networks that include wired, wireless, voice, data, multimedia, and Internet communications networks. ACE*COMM marketed and sold its solutions in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It had strategic alliances with telecommunication and Internet equipment manufacturers, computer equipment manufacturers, and telecom systems integrators. The company was founded in 1983 and was headquartered in Gaithersburg, Maryland.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Migo Software, Inc. engages in the development, acquisition, and marketing of software and infrastructure technologies designed for the storage and accession of personalized mobile information. Its flagship product, Migo, allows users to synchronize their personalized computing environments, including email, digital media, and other data; and application settings to portable storage devices, such as flash/hard disk drives, smart phones, and MP3 players. The company also offers XP to Vista Easy-Sync Suite that provides a safety net and applications support for users transitioning their data and computing environment to a new or upgraded computer running Microsoft’s Windows Vista Operating System; Registry Repair, which fixes computer problems, such as system lock-ups and freezes; PC BackUp, a disaster recovery tool that simplifies the computer backup process; and Recover Lost Data, an utility for retrieving files. In addition, it provides Digital Vault/Portable Vault, Digital File Shedder, DriveWasher, and Easy PC Transfer that offer a line of backup, system utility, and online security/privacy for the users. Migo Software sells its products primarily through original equipment manufacture partnerships, resellers, and through its Web site in the United States and internationally. The company was formerly known as Powerhouse Technologies Group, Inc. and changed its name to Migo Software, Inc. in 2006. Migo Software is headquartered in Redwood City, California.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

BravoSolution US provides on-demand supply management solutions to companies primarily in the United States and Europe. It offers various supply management software & services in areas, such as program management, spend analysis, eSourcing, contract management, and supplier performance management. The company was formerly known as Verticalnet Inc. and changed its name to BravoSolution US in January 2008. The company was incorporated in 1995 and is based in Malvern, Pennsylvania. As of January 25, 2008, BravoSolution US operates as a subsidiary of BravoSolution SpA.

Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.